These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
3. Role of plasma aluminum in the detection and prevention of aluminum toxicity. Winney RJ; Cowie JF; Robson JS Kidney Int Suppl; 1986 Feb; 18():S91-5. PubMed ID: 3458005 [No Abstract] [Full Text] [Related]
4. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine]. Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK Dtsch Med Wochenschr; 1989 Feb; 114(7):253-7. PubMed ID: 2917487 [TBL] [Abstract][Full Text] [Related]
10. [Aluminum poisoning in dialysis patients--diagnosis and therapy]. Vogelsang U Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059 [TBL] [Abstract][Full Text] [Related]
11. Risk of aluminium intoxication in long-term acetate Redy dialysis. Van de Vyver FL; Visser WJ; D'Haese PC; Silva FJ; Thomas H; De Broe ME Nephrol Dial Transplant; 1989; 4(6):555-62. PubMed ID: 2507978 [TBL] [Abstract][Full Text] [Related]
12. Liver granulomatosis is not an exceptional cause of hypercalcemia with hypoparathyroidism in dialysis patients. Hardy P; Morinière PH; Tribout B; Hamdini N; Marié A; Bouffandeau B; Pruna A; Fournier A J Nephrol; 1999; 12(6):398-403. PubMed ID: 10626831 [TBL] [Abstract][Full Text] [Related]
13. [Detecting and evaluating hyperaluminemia in 3 dialysis centers]. Balabán D; Simícková J; Kubátko J; Syrovátka P Cas Lek Cesk; 1989 Dec; 128(51):1611-4. PubMed ID: 2631999 [TBL] [Abstract][Full Text] [Related]
14. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia. O'Brien AA; McParland C; Keogh JA Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649 [TBL] [Abstract][Full Text] [Related]
15. Incidence of hypercalcaemia in haemodialysis patients. Pascual N; Andrea C; Zaleski M; Hernandez J; Goicoechea M EDTNA ERCA J; 1997; 23(3):48-50. PubMed ID: 9664010 [TBL] [Abstract][Full Text] [Related]
16. Calcium metabolism and hyperparathyroidism after renal transplantation. Cundy T; Kanis JA; Heynen G; Morris PJ; Oliver DO Q J Med; 1983; 52(205):67-78. PubMed ID: 6348830 [TBL] [Abstract][Full Text] [Related]
17. Improved bone formation in dialysis patients after substitution of calcium carbonate for aluminum gels. Hercz G; Andress DL; Norris KC; Shinaberger JH; Slatopolsky EA; Sherrard DJ; Coburn JW Trans Assoc Am Physicians; 1987; 100():139-46. PubMed ID: 3455064 [No Abstract] [Full Text] [Related]
18. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder. Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365 [TBL] [Abstract][Full Text] [Related]
19. [Aluminium poisoning in uremic children]. Hinojosa-Lezama M; Gordillo-Paniagua G Bol Med Hosp Infant Mex; 1986 Sep; 43(9):532-6. PubMed ID: 3790225 [No Abstract] [Full Text] [Related]
20. [Two forerunners of the encephalopathy of hemodialysed patients : osteomalacic osteodystrophy and electroencephalographic alterations. Influence of the aluminium concentration in the dialysis fluid (author's transl)]. Vecchierini-Blineau MF; Thébaud HE; Brochard D; Coville P Nephrologie; 1980; 1(1):29-32. PubMed ID: 7301017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]